myelodysplastic syndromes (MDS) | Page 104 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

Author(s): 
Sekeres MA, Steensma DP
Primary Author: 
Sekeres MA
Journal Title: 
Blood
Original Publication Date: 
Jul 2009

The recent approval of 3 drugs for the treatment of myelodysplastic syndromes (MDSs) has resulted in a revolution in therapeutic options that was absent a decade ago. At the same time, the changing MDS

Bone Marrow Diseases: 

Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.

Author(s): 
Silverman LR
Primary Author: 
Silverman LR
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2009

The implication of DNA hypermethylation in the pathogenesis of

Bone Marrow Diseases: 

Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.

Author(s): 
Warlick ED
Primary Author: 
Warlick ED
Journal Title: 
Curr Opin Oncol
Original Publication Date: 
Mar 2010

PURPOSE OF REVIEW:

Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative therapy for myelodysplastic syndrome (MDS). Recent efforts to optimize the curative potential of transplant have focused on pretransplant therapy options, the use of predictive models to improve patient selection, and transplant modifications using reduced conditioning intensity. This review highlights strategies to optimize transplant for MDS and identifies unresolved questions.

Bone Marrow Diseases: